Drilldown: Medicines

Other values:

Search

None (69) · Captagon (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Dexedrine (1) · Focalin, Focalin XR (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

1-acetyl-LSD; prodrug of LSD (1) · 5-HT2A agonist (26) · 5-HT2A agonist; D2 partial agonist (1) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · 5-HT2A partial agonist (1) · Contains bufotenin and DMT (1) · Contains LSA (2) · Contains mescaline (2) · Contains psilocybin and psilocin (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · LSD analogue; 5-HT2A agonist (4) · Lysergic acid 2,4-dimethylazetidide; 5-HT2A agonist (1) · Lysergic acid hydroxyethylamide; 5-HT2A agonist (1) · Monoamine releasing agent (1) · Monoamine releasing agent; 5-HT2A agonist (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent 5-HT2A agonist; very long duration (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of amphetamine + theophylline (1) · Prodrug of LSD; 5-HT2A agonist (4) · Prodrug of psilocin; 5-HT2A agonist (1) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Very potent 5-HT2A agonist; long duration (1)

None (72) · ADHD, narcolepsy (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1)

None (74)

None (74)

None · Indication-specific · 40 mg/d · 10 mg/d · 20 mg/d · 80 mg/d · 10 mg/d (adults) · 100 mg/d · 4 g/d · 400 mg/d · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison · 5 mg/d · 50 mg/d · 600 mg/d · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals · No fixed maximum; titrated to TSH target · TID per eye · Titrated to glucose; no fixed ceiling · Titrated to glucose; no fixed maximum · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60

Other values:

Search

None (71) · Oral (3) · transdermal (1)

None (71) · 20–60 min (oral) (1) · 30–60 min (1) · 30–60 minutes (1)

None (71) · 8–12 hours (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 8–12 h (1)

None (71) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1) · 3–5 hours (1)

None (71) · 70–90% (oral) (1) · ~22–25% (1) · ~30% (high first-pass) (1)

None (71) · Category C (1) · Not established (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (71) · Schedule I (United States) (1) · Schedule II (2)